

# Martin J Sadowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4229756/publications.pdf>

Version: 2024-02-01

31  
papers

725  
citations

759233

12  
h-index

610901

24  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18787-18792.	7.1	149
2	The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 672-681.	3.1	80
3	Blocking the Interaction between Apolipoprotein E and A $\beta$ 2 Reduces Intraneuronal Accumulation of A $\beta$ 2 and Inhibits Synaptic Degeneration. <i>American Journal of Pathology</i> , 2013, 182, 1750-1768.	3.8	70
4	A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. <i>Neurobiology of Aging</i> , 2008, 29, 836-847.	3.1	60
5	Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. <i>Neurobiology of Disease</i> , 2009, 34, 267-278.	4.4	42
6	Blocking the apoE/A $\beta$ 2 interaction ameliorates A $\beta$ 2-related pathology in APOE $\epsilon$ 2 and $\epsilon$ 4 targeted replacement Alzheimer model mice. <i>Acta Neuropathologica Communications</i> , 2014, 2, 75.	5.2	42
7	Preventing $\beta$ -amyloid fibrillization and deposition: $\beta$ -sheet breakers and pathological chaperone inhibitors. <i>BMC Neuroscience</i> , 2008, 9, S5.	1.9	41
8	Blocking the apoE/A $\beta$ 2 interaction ameliorates A $\beta$ 2-related pathology in APOE $\epsilon$ 2 and $\epsilon$ 4 targeted replacement Alzheimer model mice. <i>Acta Neuropathologica Communications</i> , 2014, 2, 75.	5.2	36
9	Modulation of amyloid precursor protein expression reduces $\beta$ -amyloid deposition in a mouse model. <i>Annals of Neurology</i> , 2014, 75, 684-699.	5.3	26
10	APOE Genotype Differentially Modulates Effects of Anti-A $\beta$ 2, Passive Immunization in APP Transgenic Mice. <i>Molecular Neurodegeneration</i> , 2017, 12, 12.	10.8	25
11	Peroxiredoxin 6 mediates protective function of astrocytes in A $\beta$ 2 proteostasis. <i>Molecular Neurodegeneration</i> , 2020, 15, 50.	10.8	22
12	Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo. <i>Neurochemistry International</i> , 2015, 90, 152-165.	3.8	21
13	Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal Degradation. <i>Molecular Neurobiology</i> , 2019, 56, 2073-2091.	4.0	13
14	Segmented Linear Mixed Model Analysis Reveals Association of the APOE $\epsilon$ 4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 921-937.	2.6	13
15	1MeTIO Provides Protection Against A $\beta$ 2-Induced Reduction of Surface Expression of Synaptic Proteins and Inhibits H2O2-Induced Oxidative Stress in Primary Hippocampal Neurons. <i>Neurotoxicity Research</i> , 2014, 25, 348-357.	2.7	11
16	In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APPSW and APPSW/PS1L166P Alzheimer's transgenic mice. <i>Neurochemistry International</i> , 2012, 61, 976-980.	3.8	10
17	Differential molecular chaperone response associated with various mouse adapted scrapie strains. <i>Neuroscience Letters</i> , 2013, 538, 26-31.	2.1	9
18	Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment). <i>Journal of Alzheimer's Disease</i> , 2019, 67, 685-705.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Detection of Cerebrovascular Loss in the Normal Aging C57BL/6 Mouse Brain Using in vivo Contrast-Enhanced Magnetic Resonance Angiography. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 585218.	3.4	9
20	APOE genotype and Alzheimer's immunotherapy. <i>Oncotarget</i> , 2017, 8, 39941-39942.	1.8	7
21	Prominent Neuroleptic Sensitivity in a Case of Early-onset Alzheimer Disease due to Presenilin-1 G206A Mutation. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 190-195.	0.9	6
22	Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 509-513.	2.6	6
23	Absence of Apolipoprotein E is associated with exacerbation of prion pathology and promotes microglial neurodegenerative phenotype. <i>Acta Neuropathologica Communications</i> , 2021, 9, 157.	5.2	6
24	Infections of the Nervous System. , 2008, , 1567-1581.		4
25	Apolipoprotein E4 Effects a Distinct Transcriptomic Profile and Dendritic Arbor Characteristics in Hippocampal Neurons Cultured in vitro. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 845291.	3.4	2
26	Circulating Angiogenic Cells and Alzheimer's Disease: Contribution of the Bone Marrow to the Pathogenesis of the Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1241-1243.	2.6	1
27	O5-03-01: Apolipoprotein E Genotype Differentially Modulates Effects of ANTI-AB Immunotherapy. , 2016, 12, P381-P382.		1
28	Reply. <i>Annals of Neurology</i> , 2014, 76, 630-631.	5.3	0
29	[P1â€“234]: ANTIâ€“PRP MAB 6D11 DISRUPTS CELLULAR TRAFFICKING OF PRP <sup>C</sup> AND PRP <sup>SC</sup> AND TARGETS PRP <sup>SC</sup> FOR LYSOSOMAL DEGRADATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P333.	0.8	0
30	[P2â€“060]: CHARACTERIZATION OF A SMALLâ€“MOLECULE APP TRANSLATION INHIBITOR FOR ALZHEIMER'S DISEASE PREVENTION AND THERAPY. <i>Alzheimer's and Dementia</i> , 2017, 13, P627.	0.8	0
31	Editorial: Translational Control of APP Expression for Alzheimer Disease Therapy. <i>Annals of Pharmacology and Pharmaceutics</i> , 2017, 2, .	0.0	0